(Q37866137)

24 August 2017

1 reference

title

Common toxicities of mammalian target of rapamycin inhibitors (English)

1 reference

24 August 2017

1 reference

Scott A Soefje

1

1 reference

24 August 2017

Anand Karnad

series ordinal

2

1 reference

24 August 2017

Andrew J Brenner

series ordinal

3

1 reference

24 August 2017

publication date

16 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

6

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

125-129

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

mTOR inhibitor-associated dermatologic and mucosal problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Phase I study of everolimus in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Sirolimus-associated pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Comprehensive lung injury pathology induced by mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Hypophosphatemia: an update on its etiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0174-9

Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus

21 January 2018

1 reference

12 December 2020

Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)

1 reference

12 December 2020

Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation

1 reference

12 December 2020

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients

1 reference

12 December 2020

10.1007/S11523-011-0174-9

Identifiers

DOI

1 reference

24 August 2017

1 reference